首页> 美国卫生研究院文献>Journal of Cancer >KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients
【2h】

KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients

机译:KRAS G12V突变是中国胃癌患者的不良预后因素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study aims to investigate the molecular characteristics of Chinese gastric cancer patients. In our study, the KRAS, BRAF, and PIK3CA mutation status of 485 GC patients were analyzed by Sanger sequencing. Kaplan-Meier analysis was used to plot survival curves according to different genotypes. The results show that the frequency of KRAS, BRAF and PIK3CA mutations were 4.1%, 1.2% and 3.5%, respectively. BRAF mutations were significantly concentrated in stage III and IV gastric cancer (P=0.009). KRAS G12V mutation carriers have much shorter OS than other mutation carriers and wild-type group patients (P=0.013). In conclusion, only the KRAS G12V mutation has an adverse effect on patient survival.
机译:本研究旨在探讨中国胃癌患者的分子特征。在我们的研究中,通过Sanger测序分析了485名GC患者的KRAS,BRAF和PIK3CA突变状态。 Kaplan-Meier分析用于根据不同基因型绘制存活曲线。结果表明,KRAS,BRAF和PIK3CA突变的频率分别为4.1%,1.2%和3.5%。在第三和第四阶段胃癌中,BRAF突变明显集中(P = 0.009)。 KRAS G12V突变携带者的OS比其他突变携带者和野生型组患者短得多(P = 0.013)。总之,只有KRAS G12V突变对患者的生存有不利影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号